This week on BioTech Nation, we explore what happens when your immune system overreacts. Professor Niels Riedemann, CEO of InflaRx, explains how the body’s defense system can sometimes cause more harm than good, leading to serious conditions like rheumatoid arthritis, severe COVID-19, and lung failure. Learn how InflaRx is developing treatments to calm the immune system and why their breakthrough drug is getting attention from U.S. health agencies.
This week on Biotech Nation, Dr. Ari Azhir, Founder and CEO of Neuvivo, shares the incredible journey of an ALS drug that was once abandoned, but is now making its way toward FDA approval. After two failed phase two trials, the drug was left behind until Dr. Azhir and her team discovered a crucial mistake in the trial data. Now with new insights and groundbreaking survival results, Neuvivo is giving hope to ALS patients and exploring its potential for other neurodegenerative diseases like Huntington’s and Alzheimer’s.
This week on BioTech Nation, Bruin Biometrics CEO Martin Burns talks about a new diagnostic tool being used to detect and prevent potentially fatal bedsores in their earliest stages.
For years, we've all turned to Google to self-diagnose every cough, rash, and weird pain. Dr. Daniel Kraft says the shift is happening, from Dr. Google to Dr. ChatGPT.
This week on Biotech Nation, Dr. Lincoln Nadauld shares how Culmination Bio is using 9 million preserved tissue samples and decades of patient data to improve how we understand and treat diseases. From discovering patterns in cancer treatments to exploring breakthroughs in heart and autoimmune diseases, this unique approach is changing medicine.
What if we could fix the gene that causes dementia? In this episode, Aviado Bio CEO Lisa Deschamps tells us how her team is working to correct the gene driving many cases of frontotemporal dementia.
What if you could tune your DNA to fix any mistakes? Dr. Derek Jantz from Tune Therapeutics talks about tuning DNA, not just with humans, but stopping the Hepatitis B virus in its tracks.
Imagine a world where the toughest wounds heal twice as fast, and patients get their lives back sooner than anyone thought possible. Dr. Ned Swanson, the President and Chief Medical Officer of Polarity Bio, tells us about their approach to healing serious, hard-to-treat skin wounds. In early trials, it's twice as effective as the current treatment for diabetic foot ulcers.
40% of all rheumatoid arthritis patients do not respond to any of the current drugs. Rob Armstrong, CEO of Artax Biopharma, aims to bring new hope for those patients who've been left without effective treatment options.
Can you imagine parents expecting a baby, going in for an ultrasound, and finding out that their baby is missing the heart's left ventricle? This week on BioTech Nation, Dr. Joshua Hare, Co-Founder and Chief Scientific Officer of Longeveron, talks about how they are testing the use of stem cells to treat babies born with a serious congenital heart defect.
This week on BioTech Nation, Dr. Jeff Stein, President & CEO of Cidara Therapeutics, brings up promising news about a new approach to flu shots.
Dr. Marc Salzberg, CEO & Chief Medical Officer of Airway Therapeutics, talks about what they are doing to help preterm babies. It may all boil down to delivering these babies a single protein as soon as they are born.
Dr. Avak Kahvejian, Founding CEO of Cellarity, explains their new approach to discovering drugs by using AI to look at how cells behave as a whole, rather than focusing on one part of the problem. This approach could lead to faster development of better treatments, such as a pill for sickle cell disease.
This week on Biotech Nation, Paul Hastings, CEO of Nkarta and former chair of BIO—the Biotechnology Innovation Organization—discusses the impact of cuts to research funding and stepping away from recommending vaccines—what this means for you and the biotech industry.
This week on BioTech Nation, Dr. Mark Kendall, CEO of WearOptimo, tells us about progress with their new wearable. You could be dehydrated and not even know it … And exactly how hydrated are you right now, anyway? The old “if you’re thirsty, drink something” turns out to be a little too late.
Tech Nation Health Chief Correspondent Daniel Kraft reports in on the BioTech Nation session from NextMed Health 2025
This week on BioTech Nation, Dr. Steve Harr, CEO of Sana Biotechnology, talks about their progress in Type I diabetics, in particular. The New England Journal of Medicine publishes early success with Sana Biotechnology's engineered insulin-producing cells without immunosuppressant drugs.
This week on BioTech Nation, Dr. Neal Kassell, founder of the Focused Ultrasound Foundation, introduces us to a powerful, non-invasive technology that’s already changing lives, and it doesn’t involve surgery, injections, or pills.
This week on BioTech Nation, Dr. Raza Bokhari, CEO of Medicus Pharma, shares a new non-surgical treatment approach for basal cell carcinoma, the most common form of skin cancer. Their novel microneedle patch delivers a powerful cancer drug directly into the skin, avoiding the scarring, cost, and discomfort of Mohs surgery. With promising phase 2 trials underway in the US and Europe, this could change the way we treat millions of skin cancer cases every year.
This week on BioTech Nation, Dr. Eric Topol returns to continue his conversation on, "Super Agers … An Evidenced-Based Approach to Longevity", his evidence-based approach to living longer, healthier lives. He shares why longevity must be accessible to everyone, not just the wealthy, and how new tools like AI, personalized diagnostics, and even gut hormones are reshaping the future of health.